<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03230851</url>
  </required_header>
  <id_info>
    <org_study_id>006</org_study_id>
    <nct_id>NCT03230851</nct_id>
  </id_info>
  <brief_title>the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy</brief_title>
  <official_title>the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 210 coronary atherosclerosis patients without indications for stent implantation
      are included. The baseline values of platelet aggregation rate, plasmaThromboxaneB2 and
      urinary 11-dh ThromboxaneB2 are measured by Light Transmittance Aggregometry method and ELISA
      after aspirin 100 mg /d ≥5d. Then the patients are randomly divided into 7 groups: Group1:
      aspirin 100 mg/d; Group2: aspirin 100 mg /2d; Groups3: aspirin 100 mg / 3d; Groups4: morning
      50mg evening 50mg; Group5: aspirin 75mg / d; Group6: aspirin 50mg / d; Group7: indobufen100mg
      bid. One month later,arachidonic acid-induced platelet aggregation rate , plasma TXB2 and
      urine 11-dh TXB2 are analyzed again. All patients are followed-up for 1 year. The stomach
      Intestinal reactions, small bleeding events are recorded.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 210 coronary atherosclerosis patients without indications for stent implantation
      are included. Exclusion criteria：Aspirin resistance, uncontrolled hypertension (&gt; 160 /
      100mmHg),hemoglobin concentration &lt;100g /L, hemorrhagic disease or a history of bleeding
      tendency, taking other nonsteroidal drugs, severe liver disease history, malignant tumor,
      active gastric mucosa bleeding, percutaneous coronary intervention history, coronary artery
      bypass surgery, cardiac function grade Ⅳ.The baseline values of platelet aggregation rate,
      plasma TXB2 and urinary 11-dh TXB2 are measured by LTA method and ELISA after aspirin 100 mg
      /d ≥5d. Then the patients are randomly divided into 7 groups: Group1: aspirin 100 mg/d;
      Group2: aspirin 100 mg /2d; Groups3: aspirin 100 mg / 3d; Groups4: morning 50mg evening 50mg;
      Group5: aspirin 75mg / d; Group6: aspirin 50mg / d; Group7: indobufen100mg bid. One month
      later,arachidonic acid-induced platelet aggregation rate , plasma TXB2 and urine 11-dh TXB2
      are analyzed again. All patients are followed-up for 1month,6months and1 year. The stomach
      Intestinal reactions, small bleeding events ,whether to take proton pump inhibitors are
      recorded.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 20, 2017</start_date>
  <completion_date type="Anticipated">August 10, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>platelet aggregation</measure>
    <time_frame>2 hours</time_frame>
    <description>Regional differences between blood samples from each subjects of different groups by LTA.The results of LTA are reported in platelet aggregation rate(%).Platelet aggregation was induced by0.5mg/ml arachidonic acid (AA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma thromboxaneB2</measure>
    <time_frame>3montshs</time_frame>
    <description>The plasma thromboxane B2 concentration of each subjects are measured by enzyme-linked immunosorbent assay .(cayman chemical, thromboxaneB2 express EIA kit-Monoclonal)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>urine 11-dehydro thromboxaneB2</measure>
    <time_frame>3 months</time_frame>
    <description>The urine 11-dehydro thromboxane B2 concentration of each subjects are measured by ELISA.(cayman chemical,11-dehydro thromboxaneB2 ELISA kit-Monoclonal)</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Coronary Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>aspirin 100mg/d therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group1: aspirin 100 mg/d;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin 100mg/2d therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group2: aspirin ;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin 100mg/3d therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Groups3: aspirin ;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin 50mg bid therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Groups4: morning 50mg evening 50mg;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin 75mg/d therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group5: aspirin 75mg / d;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin 50mg/d therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group6: aspirin 50mg / d;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>indobufen 100mg bid therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group7: 100mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin 100mg/d therapy</intervention_name>
    <description>100mg aspirin for at least 5 days followed by aspirin 100mg/d</description>
    <arm_group_label>aspirin 100mg/d therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin 100mg/2d therapy</intervention_name>
    <description>100mg aspirin for at least 5 days followed by aspirin 100mg/2d</description>
    <arm_group_label>aspirin 100mg/2d therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin 100mg/3d therapy</intervention_name>
    <description>100mg aspirin for at least 5 days followed by aspirin 100mg/3d</description>
    <arm_group_label>aspirin 100mg/3d therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin 50mg bid therapy</intervention_name>
    <description>100mg aspirin for at least 5 days followed by aspirin 50mg bid</description>
    <arm_group_label>aspirin 50mg bid therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin 75mg/d therapy</intervention_name>
    <description>100mg aspirin for at least 5 days followed by aspirin 75mg/d</description>
    <arm_group_label>aspirin 75mg/d therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin 50mg/d therapy</intervention_name>
    <description>100mg aspirin for at least 5 days followed by aspirin 50mg/d</description>
    <arm_group_label>aspirin 50mg/d therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indobufen 100mg bid therapy</intervention_name>
    <description>100mg aspirin for at least 5 days followed by indobufen 100mg bid</description>
    <arm_group_label>indobufen 100mg bid therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Clinical diagnosis of coronary atherosclerosis without indications for stent implantation .

        Patient aged &gt;18 years and ≤75years. Must be able to swallow tablets

        Exclusion Criteria:

        Aspirin resistance; uncontrolled hypertension (&gt; 160 / 100mmHg); hemoglobin &lt;100g / L;
        hemorrhagic disease or bleeding tendency history; taking other non-steroidal drugs; severe
        liver disease history; malignant neoplasms; active gastric mucosa bleeding; PCI history;
        coronary artery bypass surgery; cardiac function grade Ⅳ.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Li Chunjian, Ph.D</last_name>
    <phone>+86-25-83718836</phone>
    <phone_ext>6018</phone_ext>
    <email>lijay@njmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mei Lianlian</last_name>
    <phone>17766092046</phone>
    <email>Maylianlian1989@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2017</study_first_submitted>
  <study_first_submitted_qc>July 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2017</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Chunjian Li</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Light Transmittance Aggregometry</keyword>
  <keyword>Indobufen</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Plasma Thromboxane</keyword>
  <keyword>Urine 11-dehydro thromboxane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Indobufen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

